Xencor (NASDAQ:XNCR - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Thursday.
Other research analysts have also recently issued research reports about the company. Wells Fargo & Company lowered their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Piper Sandler upgraded Xencor from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. JPMorgan Chase & Co. lifted their price objective on Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. BMO Capital Markets reiterated an "outperform" rating and set a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Wedbush reissued an "outperform" rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $34.38.
Read Our Latest Report on XNCR
Xencor Stock Up 0.1 %
Shares of XNCR traded up $0.02 on Thursday, reaching $13.87. The stock had a trading volume of 430,444 shares, compared to its average volume of 541,108. The firm has a market capitalization of $977.31 million, a price-to-earnings ratio of -4.33 and a beta of 0.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a 50-day simple moving average of $18.39 and a 200-day simple moving average of $20.59. Xencor has a 12-month low of $13.42 and a 12-month high of $27.24.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to analysts' expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Sell-side analysts predict that Xencor will post -3.68 EPS for the current year.
Institutional Trading of Xencor
Several large investors have recently modified their holdings of XNCR. KBC Group NV grew its holdings in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 1,213 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of Xencor by 127.3% in the third quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company's stock worth $2,340,000 after acquiring an additional 65,180 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Xencor in the third quarter worth $362,000. Intech Investment Management LLC bought a new stake in shares of Xencor in the third quarter worth $368,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Xencor by 7.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company's stock worth $12,609,000 after acquiring an additional 40,788 shares during the period.
About Xencor
(
Get Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
